Why Bill Gates is “Most Excited” About The Promise of Monoclonal antibodies for COVID-19: Evidence Deep Dive .

Monoclonal antibodies have emerged as one of the most anticipated therapeutic options for COVID-19, with dozens of trials now underway across the globe. Most studies focus on agents like tocilizumab and other IL-6 or GM-CSF blockers aimed at blunting the cytokine-driven inflammation seen in severe disease. Evidence to date comes almost entirely from observational studies, which suggest a possible reduction in mortality—about 60% relative improvement—but with low certainty due to bias and inconsistency. Safety signals have been mixed but generally manageable, with no clear pattern of treatment-related harm. With more than 80 trials in progress, including several large RCTs, stronger evidence is on the way, but for now confidence in benefit remains limited and conclusions should be cautious.